Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xlife Sciences AGXSWX:XLS +0.66%37 Future 3-5Y EPS without NRI Growth Rate is 11.10 as of Aug. 24, 2026. GuruFocus rates XSWX:XLS with a GF Score™ of 37/100 and a GF Value™ of CHF7.04 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 397 Biotechnology companies, Xlife Sciences AG ranks worse than 68.77% on this metric.
Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
As of today, Xlife Sciences AG's Future 3-5Y EPS without NRI Growth Rate is 11.10.
Xlife Sciences AG (XSWX:XLS) Future 3-5Y EPS without NRI Growth Rate Explanation
Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.
Xlife Sciences AG Future 3-5Y EPS without NRI Growth Rate Related Terms
XSWX:XLS vs VRTX, REGN, RVMD: Future 3-5Y EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Xlife Sciences AG's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xlife Sciences AG Future 3-5Y EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Xlife Sciences AG's Future 3-5Y EPS without NRI Growth Rate falls into.
What does a Future 3-5Y EPS without NRI Growth Rate of 11.10 mean?
Xlife Sciences AG (XSWX:XLS) has a Future 3-5Y EPS without NRI Growth Rate of 11.10 as of Aug. 24, 2026. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for Xlife Sciences AG and its competitors. According to the industry distribution chart, Xlife Sciences AG ranks #273 out of 397 companies in the Biotechnology industry, placing it in the top 68.8%.
Is Xlife Sciences AG's Future 3-5Y EPS without NRI Growth Rate too high?
Xlife Sciences AG's current Future 3-5Y EPS without NRI Growth Rate is 11.10. The Biotechnology industry median Future 3-5Y EPS without NRI Growth Rate is 22.04. Xlife Sciences AG's value of 11.10 is 49.6% below this industry median. Based on the distribution chart, Xlife Sciences AG ranks #273 out of 397 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Xlife Sciences AG has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's Future 3-5Y EPS without NRI Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xlife Sciences AG ranks #273 out of 397 companies for Future 3-5Y EPS without NRI Growth Rate. This places Xlife Sciences AG in the lower half of its industry. The industry median Future 3-5Y EPS without NRI Growth Rate is 22.04. Xlife Sciences AG's value of 11.10 is 49.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Future 3-5Y EPS without NRI Growth Rate for a Biotechnology company?
The median Future 3-5Y EPS without NRI Growth Rate among Biotechnology companies is 22.04, based on 397 companies in the industry. Companies in the top quartile (top 25%) have a Future 3-5Y EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, Future 3-5Y EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xlife Sciences AG's current Future 3-5Y EPS without NRI Growth Rate of 11.10 is 49.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Future 3-5Y EPS without NRI Growth Rate mean?
A high Future 3-5Y EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for Xlife Sciences AG and its competitors. For the Biotechnology industry, the median Future 3-5Y EPS without NRI Growth Rate is 22.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xlife Sciences AG's current Future 3-5Y EPS without NRI Growth Rate is 11.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.04, compared to a current price of CHF15.20 — trading 115.9% above its estimated fair value. The current Future 3-5Y EPS without NRI Growth Rate is 11.10 and 49.6% below the Biotechnology industry median of 22.04. Xlife Sciences AG's overall GF Score™ is 37/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Future 3-5Y EPS without NRI Growth Rate calculated?
Future 3-5Y EPS without NRI Growth Rate is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current Future 3-5Y EPS without NRI Growth Rate is 11.10 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?
Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued.
The current stock price of CHF15.20 is trading 115.9% above its estimated GF Value™ of CHF7.04.
GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.
Key valuation signals for XSWX:XLS:
Future 3-5Y EPS without NRI Growth Rate: 11.10
GF Value™: CHF7.04 vs. price of CHF15.20 (115.9% above fair value)
Industry Position: 49.6% below the Biotechnology median (#273 of 397)
No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
37GF Score
Get the complete analysis for XSWX:XLS
Future 3-5Y EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:XLS has been successfully added to your 
